Latvia vs Türkiye: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Latvia
0.0%
in 2024
Türkiye
0.0%
in 2024
Latvia rank
167th
Türkiye rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Latvia
- Türkiye
How they compare
Latvia currently reports 0.0% against 0.0% in Türkiye, a difference of 0.0%.
Across all 10 years both countries report, Türkiye has been ahead every year.
Latvia ranks 167th and Türkiye ranks 167th of 246 countries.
Türkiye has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Latvia | Türkiye | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Türkiye |
| 2020s | 0.0% | 0.1% | 0.1% | Türkiye |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Latvia or Türkiye?
- Latvia, at 0.0% against 0.0% in Türkiye as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Latvia and Türkiye?
- 0.0%, with Latvia ahead.
- How many years of comparable data are there for Latvia and Türkiye?
- 10 years are reported by both, from 2015 to 2024.
- How do Latvia and Türkiye rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Latvia ranks 167th and Türkiye ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.